Pulmonx Reports Second Quarter 2026 Financial Results
Pulmonx (Nasdaq: LUNG) reported Q2 2026 revenue of $22.8 million, down 5% year over year, with U.S. revenue at $14.2 million (-4%) and international at $8.6 million (-6%). Gross margin rose to 78%. Net loss was $10.1 million, down from $15.2 million. Full-year 2026 revenue guidance is $90 million to $92 million.
How this was made
The 30-second read
Why it matters
The key market-moving elements are the updated FY 2026 revenue range ($90M-$92M), gross margin expectation (about 76%), and operating expense range ($109M-$111M), alongside Q2 gross margin reaching 78% and reduced losses from cost realignment.
Market read
This is a direct earnings and guidance update for LUNG, with decision-relevant numbers on revenue decline, margin improvement, loss reduction, and full-year targets.
What to watch
Traders may focus too much on gross margin and underweight the magnitude of the year-over-year revenue decline and the dependency on China registration timing for international re-acceleration.
Background
Pulmonx is a Nasdaq-listed company focused on minimally invasive treatments for lung disease; this release covers Q2 2026 results and FY 2026 guidance.
Ticker impact
Pulmonx reported Q2 2026 revenue of $22.8M, record 78% gross margin, and guided FY 2026 revenue to $90M-$92M.
Likely modest volatility around the open as traders weigh revenue decline versus margin improvement and operating expense reduction, with guidance anchoring expectations.
The article includes multiple new, decision-relevant figures: Q2 revenue/margins, net loss and adjusted EBITDA loss reductions, and explicit FY 2026 revenue, gross margin, and operating expense ranges.
Market effects
Signals improving profitability discipline in minimally invasive lung disease treatment, but highlights ongoing demand/regulatory friction in China.
International weakness is attributed to lack of sales into China pending renewal of a registration certificate, making China-specific updates a key swing factor.
Limited spillover beyond the small-cap medtech space; the main read-through is on how quickly cost realignment translates into sustainable revenue growth.
Counterpoint
Margin and cost leverage may not translate into revenue growth soon, especially with China sales paused until registration renewal.
Key entities
- companyPulmonx Corporation
Reported Q2 2026 financial results and provided updated full-year 2026 guidance.
- executiveGlen French
CEO who commented on commercial strategy execution, clinical initiatives, and expected operating leverage.
